"The company's API manufacturing facility at Panoli, Gujarat has successfully passed periodical inspection by US Food and Drug Administration (USFDA) with two minor procedural observations," J B Chemicals and Pharmaceuticals said in a BSE filing.
The company said these observations do not impact continuity of its business and it would continue its manufacturing activities in Current Good Manufacturing Practice (CGMP) compliant manner.
"The company proposes to address these observation in next 30 days," it added.
The inspection was carried out from May 7 to May 11, 2018.
The stock was trading at Rs 311.15, down 2.80 per cent, on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)